Seelos Financial Statements From 2010 to 2024

SEEL Stock  USD 0.30  0.03  9.09%   
Seelos Therapeutics financial statements provide useful quarterly and yearly information to potential Seelos Therapeutics investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Seelos Therapeutics financial statements helps investors assess Seelos Therapeutics' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Seelos Therapeutics' valuation are summarized below:
Gross Profit
-46.6 M
Market Capitalization
4.5 M
Enterprise Value Revenue
220.4554
Revenue
2.2 M
Earnings Share
(7.73)
There are over one hundred nineteen available fundamental trend indicators for Seelos Therapeutics, which can be analyzed over time and compared to other ratios. We recommend to double-check Seelos Therapeutics' current fundamental drivers against the all of the trends between 2010 and 2024. The value of Market Cap is estimated to slide to about 6.5 M. The Enterprise Value is projected to slide to about 17.1 M

Seelos Therapeutics Total Revenue

2.69 Million

Check Seelos Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Seelos main balance sheet or income statement drivers, such as Depreciation And Amortization of 54.1 K, Interest Expense of 71.2 K or Selling General Administrative of 8.7 M, as well as many exotic indicators such as Price To Sales Ratio of 3.38, Dividend Yield of 0.0038 or Days Sales Outstanding of 104. Seelos financial statements analysis is a perfect complement when working with Seelos Therapeutics Valuation or Volatility modules.
  
This module can also supplement Seelos Therapeutics' financial leverage analysis and stock options assessment as well as various Seelos Therapeutics Technical models . Check out the analysis of Seelos Therapeutics Correlation against competitors.
For more information on how to buy Seelos Stock please use our How to buy in Seelos Stock guide.

Seelos Therapeutics Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets5.1 M5.4 M16.6 M
Pretty Stable
Short and Long Term Debt Total7.5 M14.2 M7.9 M
Slightly volatile
Total Current Liabilities40.9 M38.9 M13.9 M
Slightly volatile
Accounts Payable17.2 M16.4 M3.7 M
Slightly volatile
Cash2.8 MM13.2 M
Pretty Stable
Cash And Short Term Investments2.8 MM13.2 M
Pretty Stable
Common Stock Total Equity129.2 K123 K52.5 K
Slightly volatile
Common Stock Shares Outstanding5.1 M4.9 M1.4 M
Slightly volatile
Liabilities And Stockholders Equity5.1 M5.4 M16.6 M
Pretty Stable
Other Current Assets1.7 M1.6 M743.6 K
Slightly volatile
Other Stockholder Equity185.6 M219.1 M217.1 M
Very volatile
Total Liabilities40.9 M38.9 M17.1 M
Slightly volatile
Total Current Assets5.1 M5.4 M15.4 M
Pretty Stable
Short Term Debt14.9 M14.2 M5.7 M
Slightly volatile
Common Stock9.5 K10 K36.9 K
Slightly volatile
Current Deferred Revenue1.091.15918.7 K
Pretty Stable
Inventory0.860.9478.5 K
Slightly volatile
Short Term Investments641.2 K675 K1.2 M
Slightly volatile
Good Will966.1 KM1.6 M
Slightly volatile
Intangible Assets2.5 M2.4 M2.7 M
Slightly volatile
Long Term Debt Total4.2 M8.4 M5.6 M
Slightly volatile
Capital Surpluse189.3 M183.6 M230.6 M
Slightly volatile
Deferred Long Term Liabilities1.1 M624.6 KM
Slightly volatile
Non Current Liabilities Other213.7 K180 K272.3 K
Slightly volatile
Property Plant Equipment61.6 K64.8 K987.6 K
Slightly volatile
Long Term Debt7.8 M9.4 M5.8 M
Slightly volatile
Short and Long Term DebtM14.2 M6.1 M
Pretty Stable
Other Liabilities258.6 K180 K493 K
Slightly volatile
Other Assets39.6 K42.5 K36.5 K
Slightly volatile
Capital Stock9.5 K10 K37.6 K
Slightly volatile

Seelos Therapeutics Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Selling General Administrative8.7 M12.6 M10.1 M
Pretty Stable
Other Operating Expenses23.6 M42.7 M27.8 M
Slightly volatile
Research Development31.6 M30.1 M17.8 M
Slightly volatile
Total Operating Expenses22.6 M42.6 M26.7 M
Slightly volatile
Non Recurring6.6 M7.4 M8.1 M
Slightly volatile
Extraordinary Items552.8 K621.9 K677.2 K
Slightly volatile
Interest Income122.5 K198 K224.6 K
Slightly volatile
Selling And Marketing Expenses45.6 K51.3 K55.9 K
Slightly volatile

Seelos Therapeutics Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow11.6 M15.5 M13.9 M
Slightly volatile
Depreciation54.1 K57 K252 K
Very volatile
End Period Cash Flow2.8 MM13.2 M
Pretty Stable
Stock Based Compensation2.3 MM2.5 M
Slightly volatile
Dividends Paid5.7 M5.4 M4.5 M
Slightly volatile
Other Cashflows From Investing Activities14.7 M14 MM
Slightly volatile
Exchange Rate Changes194.4 K218.7 K238.1 K
Slightly volatile
Issuance Of Capital Stock35.7 M20.1 M17.9 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio3.383.56616
Slightly volatile
Dividend Yield0.00380.00360.0037
Slightly volatile
Days Sales Outstanding10414583.8152
Slightly volatile
Average Payables9.5 MM8.1 M
Slightly volatile
Stock Based Compensation To Revenue1.711.630.978
Slightly volatile
EV To Sales8.959.42615
Slightly volatile
Inventory Turnover6.775.865.7513
Pretty Stable
Days Of Inventory On Hand0.0070.007456.3487
Slightly volatile
Payables Turnover0.00330.00356.7154
Very volatile
Sales General And Administrative To Revenue6.246.579.1863
Pretty Stable
Average Inventory0.430.45182.3 K
Slightly volatile
Research And Ddevelopement To Revenue29.9515.7220.9865
Pretty Stable
Cash Per Share0.580.611450.6171
Slightly volatile
Capex To Operating Cash Flow0.00150.00160.0136
Slightly volatile
Days Payables Outstanding110.3 K105 K19.6 K
Slightly volatile
Income Quality0.90.63120.863
Very volatile
Intangibles To Total Assets0.210.20.2105
Slightly volatile
Current Ratio0.130.13881.9029
Pretty Stable
Receivables Turnover2.472.68.5461
Slightly volatile
Graham Number32.7634.4889646
Slightly volatile
Average Receivables26.4 K27.8 K65.9 K
Slightly volatile
Revenue Per Share0.490.5223.1178
Slightly volatile
Interest Debt Per Share2.772.9188152
Slightly volatile
Debt To Assets2.762.62610.9172
Slightly volatile
Operating Cycle189145146
Very volatile
Days Of Payables Outstanding110.3 K105 K19.6 K
Slightly volatile
Ebt Per Ebit1.450.93541.0166
Slightly volatile
Quick Ratio0.09170.09661.7406
Pretty Stable
Cash Ratio0.07310.0771.722
Pretty Stable
Days Of Inventory Outstanding0.0070.007456.3487
Slightly volatile
Days Of Sales Outstanding10414583.8152
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.181.151.0354
Slightly volatile
Fixed Asset Turnover13913279.0878
Slightly volatile
Capital Expenditure Coverage Ratio57.2260.4753.5526
Slightly volatile
Debt Ratio2.762.62610.9172
Slightly volatile
Price Sales Ratio3.383.56616
Slightly volatile
Asset Turnover0.230.370.3413
Very volatile

Seelos Therapeutics Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap6.5 M6.8 M38.4 M
Pretty Stable
Enterprise Value17.1 M18 M29 M
Slightly volatile

Seelos Fundamental Market Drivers

Cash And Short Term InvestmentsM

Seelos Upcoming Events

13th of February 2024
Upcoming Quarterly Report
View
31st of December 2023
Next Fiscal Quarter End
View

About Seelos Therapeutics Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Seelos Therapeutics income statement, its balance sheet, and the statement of cash flows. Seelos Therapeutics investors use historical funamental indicators, such as Seelos Therapeutics's revenue or net income, to determine how well the company is positioned to perform in the future. Although Seelos Therapeutics investors may use each financial statement separately, they are all related. The changes in Seelos Therapeutics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Seelos Therapeutics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Seelos Therapeutics Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Seelos Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue 1.15  1.09 
Total Revenue2.2 M2.7 M
Cost Of Revenue57 K54.1 K
Stock Based Compensation To Revenue 1.63  1.71 
Sales General And Administrative To Revenue 6.57  6.24 
Research And Ddevelopement To Revenue 15.72  29.95 
Capex To Revenue(0)(0)
Revenue Per Share 0.52  0.49 
Ebit Per Revenue(16.55)(17.37)

Currently Active Assets on Macroaxis

When determining whether Seelos Therapeutics is a strong investment it is important to analyze Seelos Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Seelos Therapeutics' future performance. For an informed investment choice regarding Seelos Stock, refer to the following important reports:
Check out the analysis of Seelos Therapeutics Correlation against competitors.
For more information on how to buy Seelos Stock please use our How to buy in Seelos Stock guide.
Note that the Seelos Therapeutics information on this page should be used as a complementary analysis to other Seelos Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..

Complementary Tools for Seelos Stock analysis

When running Seelos Therapeutics' price analysis, check to measure Seelos Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Seelos Therapeutics is operating at the current time. Most of Seelos Therapeutics' value examination focuses on studying past and present price action to predict the probability of Seelos Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Seelos Therapeutics' price. Additionally, you may evaluate how the addition of Seelos Therapeutics to your portfolios can decrease your overall portfolio volatility.
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Money Managers
Screen money managers from public funds and ETFs managed around the world
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Is Seelos Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Seelos Therapeutics. If investors know Seelos will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Seelos Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(7.73)
Revenue Per Share
0.45
Return On Assets
(1.80)
Return On Equity
(5.84)
The market value of Seelos Therapeutics is measured differently than its book value, which is the value of Seelos that is recorded on the company's balance sheet. Investors also form their own opinion of Seelos Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Seelos Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Seelos Therapeutics' market value can be influenced by many factors that don't directly affect Seelos Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Seelos Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Seelos Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Seelos Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.